As of the latest check, Telomir Pharmaceuticals, Inc.’s (NASDAQ: TELO) stock has surged 81.40% during the morning session, trading at $2.19.
This increase comes after fresh preclinical results showed that Telomir-1, the company’s primary candidate, restores epigenetic gene silencing in aggressive prostate cancer animals more successfully than the commonly used medicines Rapamycin and Paclitaxel.
Restoring the Function of the Tumor Suppressor
The STAT1 gene, which is essential for immune surveillance and programmed cell death and is frequently silenced in advanced malignancies because of promoter hypermethylation, was successfully reactivated by Telomir-1, the company announced. The body’s natural capacity to identify and eradicate cancer cells is compromised by this suppression.
In PC3 xenograft mice models, a 21-day oral Telomir-1 therapy corrected hypermethylation in a dose-dependent manner, according to the study. By contrast, Paclitaxel showed no impact and Rapamycin only partial effectiveness in reactivating STAT1.
A Distinct Mechanism of Action
Telomir-1’s mechanism of restoring STAT1 function suggests it may help revive the body’s immune recognition of tumors, allowing immune cells to target and destroy malignant tissue. Conventional chemotherapies do not target this unique therapeutic route provided by epigenetic remodeling.
Importantly, scientists found that Telomir-1 did not cause malignant cells’ telomeres to stretch. This observation bolsters the compound’s safety profile in oncology applications.
Increasing the Potential for Therapy
These new findings support those published in March 2025, when it was demonstrated that Telomir-1, when combined with Paclitaxel, may reduce tumor volume by 50% and prevent chemotherapy-induced death. By controlling metal ions, the substance may help lessen oxidative stress, protecting healthy cells from harm while undergoing chemotherapy.
Preclinical development of Telomir-1 is being advanced by Telomir Pharmaceuticals for a number of indications, such as dysphonia, Wilson’s disease, AMD, cancer, and autism spectrum disorder.
The company plans to soon announce its first Investigational New Drug (IND) indication, demonstrating its dedication to cutting-edge treatments based on epigenetic research.